BioMarin’s “PegPal” Receives FDA Approval

BioMarin announced this week that the FDA has approved its Palynziq™ injection for treatment of adults with Phenylketonuria (PKU). Formerly known during the clinical trials as PegPal, this is the first enzyme therapy to treat PKU and has been demonstrated to significantly and substantially reduce blood Phenylalanine levels in adults. Read the full press release here.